This site is intended for healthcare professionals
Drug News

VBL presents positive interim data from the OVAL phase III pivotal study of VB 111 in ovarian cancer at the ASCO meeting, showing 58% or higher objective response rate

Read time: 1 mins
Last updated:2nd Jun 2020
Published:2nd Jun 2020
Condition: Ovarian Cancer
Type: drug
Register for free exclusive healthcare eLearning resources


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest